Axsome Therapeutics Expands Auvelity into Alzheimer's Market with Strong Early Sales
In April 2026, the FDA approved Axsome Therapeutics' drug Auvelity for agitation associated with dementia due to Alzheimer’s disease. This marks a significant expansion beyond its original indication of major depressive disorder and positions it as the first non-antipsychotic treatment in this space. Early results show strong momentum: second-quarter sales reached $180.3 million, up 51% year-over-year, with new patient starts among those aged 65+ rising by 126%. Axsome now estimates Auvelity could reach peak annual sales of at least $8 billion, split roughly evenly between depression and Alzheimer’s agitation. Axsome has expanded its commercial infrastructure to support the launch, increasing its sales force from around 300 to over 600 representatives. Insurance coverage for Auvelity now reaches approximately 89% of covered lives. In addition to Auvelity, Axsome's other products—Sunosi and Symbravo—are also showing growth potential in their respective markets. The company is also advancing its pipeline with several promising candidates like AXS-12 (for narcolepsy) and AXS-14 (for fibromyalgia), which has already shown positive Phase 3 results. Axsome aims to file an average of one new FDA drug application per year through 2030, though not all programs are expected to succeed.
Tickers: $AXSM